Viatris (VTRS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$14.7B

Revenue (quarter)

$3.8B

Revenue growth (year over year)

+4.88%

Gross profit (trailing twelve months)

$5.1B

Gross margin

34.83%

Net income (trailing twelve months)

−$410.7M

Net income (quarter)

−$118.8M

Net income growth (year over year)

−2482.61%

Net margin

−2.79%

Return on equity

−2.75%

EPS (trailing twelve months)

−$0.37

Book value per share

$12.34

P/E (trailing twelve months)

—

Price to book

1.41

Debt to assets

59.31%

Payout ratio

−15.99%

Dividend yield

2.75%

Company profile

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.

• Is Viatris (VTRS) profitable?

  No. Viatris reported a net loss of $410.7M over the trailing twelve months.

• How much revenue does Viatris (VTRS) make?

  Viatris generated $14.7B in revenue over the trailing twelve months, up 4.88% year over year.

• How do I buy stock in Viatris (VTRS)?

  VTRS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.